By Fineline Cube 
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from the National Medical Products Administration (NMPA) for its Kangmeina (tibremciclib). The approval covers the use of Kangmeina in combination with fulvestrant for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer that has progressed after prior endocrine therapy.
Mechanism of Action
Tibremciclib is a novel, fully proprietary molecular entity developed by Betta Pharmaceuticals. It targets cyclin-dependent kinases 4/6 (CDK4/6), which are key regulators of cell cycle progression. The drug specifically binds to CDK4/6 to inhibit kinase activity, blocking the cell cycle transition from G1 to S phase. This mechanism suppresses cancer cell proliferation and metastasis-related signaling pathways.-Fineline Info & Tech